Sanjivani Paranteral Valuation

Is 531569 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 531569 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 531569's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 531569's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 531569?

Key metric: As 531569 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 531569. This is calculated by dividing 531569's market cap by their current earnings.
What is 531569's PE Ratio?
PE Ratio	48.9x
Earnings	₹69.19m
Market Cap	₹3.39b

531569 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.5x
Enterprise Value/EBITDA	36.5x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 531569's PE Ratio compare to its peers?

The above table shows the PE ratio for 531569 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	21.3x
539730 Fredun Pharmaceuticals	17.9x	n/a	₹3.2b
PAR Par Drugs and Chemicals	19.8x	n/a	₹3.6b
531726 Panchsheel Organics	18.2x	n/a	₹2.6b
531739 Gennex Laboratories	29.2x	n/a	₹4.4b
531569 Sanjivani Paranteral	48.9x	n/a	₹3.4b

Price-To-Earnings vs Peers: 531569 is expensive based on its Price-To-Earnings Ratio (48.9x) compared to the peer average (21.3x).

Price to Earnings Ratio vs Industry

How does 531569's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
INDSWFTLAB Ind-Swift Laboratories	1.6x	n/a	US$70.43m
524652 Ind-Swift	2x	n/a	US$13.12m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 531569 is expensive based on its Price-To-Earnings Ratio (48.9x) compared to the Indian Pharmaceuticals industry average (31.6x).

Price to Earnings Ratio vs Fair Ratio

What is 531569's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

531569 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	48.9x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 531569's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vilin Bio Med

₹293.6m

Engages in the manufacture and sale of pharmaceutical products in India.

VILINBIO

₹21.05

7.4%

-0.9%

Venus Remedies

₹3.9b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹291.85

-3.6%

-22.2%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹928.00

-1.7%

15.6%